HOPKINTON, Mass., Jan. 5 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc., , a biotechnology company focused on diagnostic and therapeutic products for diseases of the Central Nervous System (CNS), today announced the appointment of Steven I. Engel, M.S., Pharm. D., to the position of Senior Vice President, Regulatory Affairs and Quality.
"Steve has extensive operational and management experience in the areas of strategic planning, drug development, project management and regulatory compliance," said Dr. Mark Pykett, President and COO of BLSI. "His proven track record of product registrations and development candidate life-cycle management should add immediate value to our late-stage molecular imaging program for ALTROPANE, particularly as we strive to complete our clinical trials in Parkinson's disease and prepare and submit a New Drug Application. We expect Steve will lead an efficient, focused regulatory submission plan for our product candidates, enhance and maintain our relationships with the regulatory agencies and assist in the evaluation of new CNS pipeline opportunities."
Most recently, Dr. Engel was Vice President of Regulatory Affairs and Quality at AlgoRx, Inc. (Secaucus, NJ). Prior to AlgoRx, Steve held senior regulatory positions at Cubist Pharmaceuticals, Vertex and Baxter Healthcare. He also held management positions at Abbott Laboratories, Otsuka America, GD Searle & Co. and American Cyanamid. He received his Master of Science degree from University of North Carolina at Chapel Hill and his Doctor of Pharmacy degree from University of Florida. He has held faculty positions at the College of Pharmacy and Medicine of the University of Florida and Montefiore Medical Center/Albert Einstein College of Medicine at Yashiva University. His research interests have included drug effects in the elderly and development of new anticancer agents.
About Boston Life Sciences, Inc.
Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and a Phase II clinical trial for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, O-1369 for the treatment of Parkinson's disease and FLUORATEC(TM), a second generation molecular imaging agent, for PS and ADHD. BLSI's current research collaborations include Harvard Medical School, Children's Hospital of Boston and the University of Massachusetts-Worcester.
ALTROPANE is a registered trademark of Boston Life Sciences, Inc.
The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future, including the Company's development efforts regarding the Company's ALTROPANE program and the Company's pre-clinical candidates. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on form 10-Q for the quarter ended September 30, 2005, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences, Inc. is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Contact: Sharon Correia -- 508-497-2360 ext 224
Boston Life Sciences, Inc.
